Is Zoryve Approved for Plaque Psoriasis?
Yes, Zoryve (roflumilast cream 0.3%) is FDA-approved for treating mild to moderate plaque psoriasis in adults and children 6 years and older. It targets inflammation by inhibiting phosphodiesterase-4 (PDE4), reducing itchy, scaly plaques.[1][2]
How Does Zoryve Work for Plaque Psoriasis?
Applied once daily, Zoryve blocks PDE4 enzymes that trigger inflammatory signals in skin cells. Clinical trials showed 42% of patients achieved clear or almost clear skin after 8 weeks, compared to 6% on vehicle cream. It works on all skin types and body areas, including sensitive spots like face and folds.[1][3]
What Do Trial Results Show?
In two phase 3 trials (DERMIS-1 and DERMIS-2), Zoryve cleared psoriasis plaques in about 40% of patients by week 8, with itch relief starting within days. Long-term data (52 weeks) found sustained clearance in 80% of initial responders, without tachyphylaxis (loss of effect).[2][4]
Who Makes Zoryve and When Did It Launch?
Arcutis Biotherapeutics developed Zoryve, approved by the FDA in July 2022 for plaque psoriasis. It's also approved for seborrheic dermatitis. Available by prescription; no generic yet.[1][5]
How Does Zoryve Compare to Other Psoriasis Treatments?
Unlike steroids, Zoryve has low systemic absorption and no black-box warnings for skin thinning. It outperforms vehicle controls but head-to-head data vs. topical steroids or biologics like Humira is limited. Patients often prefer it for steroid-sparing use on face/genitals.[3][6]
| Treatment | Application | Clearance Rate (8 weeks) | Common Issues |
|-----------|-------------|---------------------------|---------------|
| Zoryve | Once daily cream | ~40% | Mild burning (10-15%) |
| Mid-potency steroid | 1-2x daily | 20-30% | Thinning, rebound |
| Calcipotriene | 2x daily | 15-25% | Irritation |
What Side Effects Do Patients Report?
Most common: application-site pain (diarrhea <2%), nasopharyngitis, or headache. No serious systemic effects in trials; safe for long-term use up to 52 weeks. Diarrhea occurs in under 3%.[2][4]
When Does Zoryve's Patent Expire?
Core patents for roflumilast topical formulations extend to 2037-2041, per DrugPatentWatch.com.[7] No major challenges filed yet, delaying generics.
Sources
[1]: FDA Approval Label for Zoryve
[2]: Arcutis Press Release on DERMIS Trials
[3]: JAAD Study on Zoryve Efficacy
[4]: 52-Week Safety Data
[5]: Arcutis Biotherapeutics Overview
[6]: Comparison Review in Dermatology Times
[7]: DrugPatentWatch: Zoryve Patents